According to Pneumagen, its Neumifil carbohydrate binding module (mCBM), which it is developing as a nasal spray for the prevention and treatment of respiratory infections, significantly reduced symptoms and weight loss in a hamster model of COVID-19. Researchers also found that Neumifill demonstrated high binding affinity for the ACE2 receptor and for the SARS-CoV-2 spike protein, including for the B.1.1.7 and B.1.351 variants. In January 2021, the company said that it had raised £2.5 million for clinical development of Neumifil.
Pneumagen CEO Douglas Thomson commented, “This exciting data confirms Neumifil’s potential as a treatment against variant strains of COVID-19. Neumifil, our universal pan-viral intranasal product, targets glycans to provide both prophylaxis and treatment for COVID-19, and other emerging viruses with pandemic potential. We are preparing for a Phase 1 clinical study in mid-2021.”
Read the Pneumagen press release.
